Skip to main content
Fig. 2 | BMC Endocrine Disorders

Fig. 2

From: Enhancement of postprandial endogenous insulin secretion rather than exogenous insulin injection ameliorated insulin antibody-induced unstable diabetes: a case report

Fig. 2

Glucose levels (mg/dL) determined with a continuous glucose monitoring system for 24 h, with treatment (a) insulin lispro 3 U before meals, liraglutide 0.9 mg before breakfast and voglibose 0.2 mg before lunch and (b) mitiglinide 10 mg before meals, liraglutide 0.9 mg before breakfast and voglibose 0.2 mg before lunch. represents the time of each meal. represents capillary glucose level for sensor signal calibration

Back to article page